Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

12.42USD
2:03pm EDT
Change (% chg)

$-0.27 (-2.13%)
Prev Close
$12.69
Open
$12.79
Day's High
$12.84
Day's Low
$12.35
Volume
61,587
Avg. Vol
179,983
52-wk High
$19.91
52-wk Low
$8.70

INSY.OQ

Chart for INSY.OQ

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $915.27
Shares Outstanding(Mil.): 72.13
Dividend: --
Yield (%): --

Financials

  INSY.OQ Industry Sector
P/E (TTM): -- 212.65 15.78
EPS (TTM): -0.02 -- --
ROI: -0.46 -7.61 -8.29
ROE: -0.48 -9.04 -7.91

BRIEF-Insys Therapeutics appoints Andrew Long as chief financial officer

* Insys Therapeutics, Inc appoints Andrew G. Long as chief financial officer

Jul 18 2017

BRIEF-Insys Therapeutics Inc releases statement on payor interactions

* Insys Therapeutics says committed to establishing long-term partnerships in healthcare community with public and private payors

Jul 17 2017

Anthem files lawsuit against Insys Therapeutics

Health insurer Anthem Inc filed a lawsuit against Insys Therapeutics Inc  on Wednesday, alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.

Jul 13 2017

Anthem files lawsuit against Insys Therapeutics

Health insurer Anthem Inc filed a lawsuit against Insys Therapeutics Inc on Wednesday, alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.

Jul 13 2017

Anthem files lawsuit against Insys Therapeutics

July 13 Health insurer Anthem Inc filed a lawsuit against Insys Therapeutics Inc on Wednesday, alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.

Jul 13 2017

Ex-Insys saleswomen plead guilty in U.S. to drug kickback schemes

Two former Insys Therapeutics Inc sales representatives including the wife of its ex-chief executive pleaded guilty on Tuesday to engaging in schemes to pay kickbacks to medical practitioners to prescribe a drug containing the opioid fentanyl.

Jul 11 2017

UPDATE 2-Ex-Insys saleswomen plead guilty in U.S. to drug kickback schemes

July 11 Two former Insys Therapeutics Inc sales representatives including the wife of its ex-chief executive pleaded guilty on Tuesday to engaging in schemes to pay kickbacks to medical practitioners to prescribe a drug containing the opioid fentanyl.

Jul 11 2017

Ex-Insys CEO's wife pleads guilty in U.S. to opioid kickback scheme

A former Insys Therapeutics Inc sales representative who is married to its former chief executive pleaded guilty on Tuesday to engaging in a scheme to pay kickbacks to medical practitioners to prescribe a drug containing the opioid fentanyl.

Jul 11 2017

Ex-Insys employee pleads guilty in U.S. to opioid kickback scheme

July 11 A former Insys Therapeutics Inc sales representative pleaded guilty on Tuesday to having participated in a scheme to pay kickbacks to medical practitioners to prescribe a drug containing the opioid fentanyl, U.S. prosecutors said.

Jul 11 2017

Ex-Insys employee in U.S. kickback case loses fight to smoke pot

A U.S. judge has rejected a former Insys Therapeutics Inc employee's arguments that he had a constitutional right to use marijuana while under indictment for what federal prosecutors call a scheme to pay kickbacks to doctors to prescribe an opioid drug.

Jul 10 2017

Earnings vs. Estimates